

Press release

DELTA and 2cureX establish strategic partnership and 2cureX expands its board of directors.

Hoersholm and Copenhagen, Denmark, 31 October 2008: DELTA and 2cureX announces the signing of a strategic partnership to develop stand-alone life-science solutions that are based on 2cureX's ChemoCellomics technology. Under the terms of the agreement DELTA will apply its multidisciplinary technical development capabilities and marketing effort to the joint product development. Financial details of the agreement were not disclosed.

2cureX's ChemoCellomics® is a unique technology that integrates synthesis of large collections of individual chemical compounds with screening thereof in intact living cells. An important feature of the technology is that it for the first time allows high throughput cell-based screening in primary cells taken directly from patients with chemical structures that previously have been overwhelmingly expensive to produce.

"We are delighted to have DELTA as a strategic partner. We are convinced that this partnership is crossing traditional technical and business barriers and will result in truly novel healthcare applications to the benefit of a broad spectrum of patients. In this partnership we will leverage some of the wide applications of the ChemoCellomics technology that lie outside 2cureX's internal drug discovery efforts. We see the partnership with DELTA as a clear indication of the breath of 2cureX's core technology" says Ole Thastrup, Chief Executive Officer of 2cureX.

"We are constantly on the outlook for cutting edge technologies that can synergise with DELTA's expertises and technologies to provide novel easy-to-use solutions for numerous industrial and personal applications. We believe that the unique capabilities of the ChemoCellomics technology in combination with our expertises in Microsystems (MEMS), optics and light detection can bring truly novel life-science products to the market" commented Per Hartlev, Chief Executive Officer of DELTA.

2cureX will in consequence of this strategic alliance expand its board of directors with Per Hartlev.

Ole Bitsch-Jensen, SEED Capital, Denmark, Chairman of 2cureX's board of directors commented: "The Board warmly welcomes Per to the 2cureX team. He has shown an impressive ability to efficiently manage and market technology-based products that from idea inception to marketing are focussed on solving real customer needs. I am convinced that Per will be a valuable addition to 2cureX as we now move into exploiting the ChemoCellomics technology in stand-alone life-science applications".

Contacts:

Ole Thastrup
Chief Executive Officer, 2cureX

Tel: +45 45822036
e-mail: ot@2curex.com

Timm Jessen
Chief Business Officer 2cureX

Tel: +49 (4315) 606 448
e-mail: tj@2curex.com

Per Hartlev
Chief Executive Officer, DELTA

Tel.: +45 72 19 42 21
e-mail: phar@delta.dk



About 2cureX

2cureX

- is a drug discovery company that rapidly generates drug candidates for the treatment of defined populations of cancer patients
- is opening the field of drug discovery to hospitals and academic institutions having patient and disease knowledge

2cureX's core technology named ChemoCellomics® integrates chemical synthesis of large compound libraries with high throughput cell-based screening (HTS). The proprietary technology allows for the first time high throughput cell-based screening directly in cells from patients. This unique property allows early identification of in-vivo efficacious drug candidates.



We help ideas meet the real world

About DELTA

DELTA is known throughout the world for its position at the forefront of technological development and complex testing. The company brims with creative minds and highly skilled technicians whose job is to both develop and carry out many kinds of stringent tests for customers that plan to release new products on the market.

DELTA optimises the application of technology for success in a complex world. We specialise in design, development, test, certification and consultancy in the following areas: Electronics, microelectronics, software technology, light, optics, acoustics, vibration and sensor systems.

Since 1941 DELTA has played a leading role in Europe and with the help from DELTA, thousands of companies have enjoyed success through innovative use of new technology. The 250 employees in Denmark, Sweden and the United Kingdom cooperate with customers in more than 50 countries.